BR112017020056A2 - novos derivados 4-metóxi pirrol ou sais dos mesmos e composição farmacêutica dos mesmos compreendendo os mesmos - Google Patents
novos derivados 4-metóxi pirrol ou sais dos mesmos e composição farmacêutica dos mesmos compreendendo os mesmosInfo
- Publication number
- BR112017020056A2 BR112017020056A2 BR112017020056A BR112017020056A BR112017020056A2 BR 112017020056 A2 BR112017020056 A2 BR 112017020056A2 BR 112017020056 A BR112017020056 A BR 112017020056A BR 112017020056 A BR112017020056 A BR 112017020056A BR 112017020056 A2 BR112017020056 A2 BR 112017020056A2
- Authority
- BR
- Brazil
- Prior art keywords
- methoxy
- pharmaceutically acceptable
- pyrrol derivatives
- acceptable salts
- pharmaceutical composition
- Prior art date
Links
- OTODBDQJLMYYKQ-UHFFFAOYSA-N 3-methoxy-1h-pyrrole Chemical class COC=1C=CNC=1 OTODBDQJLMYYKQ-UHFFFAOYSA-N 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 1
- 108010083204 Proton Pumps Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000000689 peptic esophagitis Diseases 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
a presente invenção provê um derivado 4-metóxi pirrol ou um sal farmaceuticamente aceitável do mesmo, um método de preparação do mesmo, e uma composição farmacêutica contendo o mesmo. os derivados 4-metóxi pirrol ou sais farmaceuticamente aceitáveis dos mesmos de acordo com a presente invenção não somente têm excelente atividade inibitória de bomba de próton, atividade de inibição de dano gástrico e efeitos de aumento do fator defensivo, mas também excelente erradicação da atividade contra h. pylori. então, os derivados 4-metóxi pirrol ou sais farmaceuticamente aceitáveis dos mesmos podem ser efetivamente utilizados para a prevenção e tratamento de dano gastrointestinal devido a úlcera do trato gastrointestinal, gastrite, esofagite de refluxo ou h. pylori. além disso, os derivados 4-metóxi pirrol ou sais farmaceuticamente aceitáveis dos mesmos, têm atividades inibitórias contra gpcr e então podem ser efetivamente utilizados para a prevenção e tratamento de doenças mediadas pelo receptor 5-ht ou mediadas pelo receptor muscarínico de acetilcolina.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0058712 | 2015-04-27 | ||
| KR20150058712 | 2015-04-27 | ||
| KR1020160013588A KR101613245B1 (ko) | 2015-04-27 | 2016-02-03 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR10-2016-0013588 | 2016-02-03 | ||
| PCT/KR2016/004411 WO2016175555A2 (en) | 2015-04-27 | 2016-04-27 | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017020056A2 true BR112017020056A2 (pt) | 2018-06-05 |
| BR112017020056B1 BR112017020056B1 (pt) | 2023-06-13 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501755A1 (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| BR112019002275A2 (pt) | inibidores aminopirimidina de ssaos | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| PH12018502016A1 (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| BR112017006708A2 (pt) | indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| SG11201900298RA (en) | Heterocyclic compound used as fgfr inhibitor | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| MX2023012198A (es) | Composiciones de amantadina, preparaciones de estas y metodos de uso. | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
| SG11201903463PA (en) | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same | |
| BR112015023222A2 (pt) | compostos tetraidroisoquinolin-2-il-(quinazolin-4-il)metanona como inibidores do crescimento de células cancerosas | |
| BR112019001129A2 (pt) | derivado de indol usado como inibidor de crth2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2016, OBSERVADAS AS CONDICOES LEGAIS |